Ascentage Pharma Announces Completion of Equity Investment by Takeda

other

▤ Summary

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.Pursuant to the terms of the Agreement, Ascentage Pharma has allotted and issued an aggregate of 24,307,322 subscription shares to Takeda International at the share purchase price of HK$24.09850 (equivalent to approximately US$3.08549).

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies